search
Back to results

Ventricular Tachycardia in Ischemic Cardiomyopathy; a Combined Endo-Epicardial Ablation Within the First Procedure Versus a Stepwise Approach (EPILOGUE)

Primary Purpose

Ventricular Tachycardia, Ischemic Cardiomyopathy

Status
Unknown status
Phase
Not Applicable
Locations
Study Type
Interventional
Intervention
combined endo/epicardial approach
stepwise approach
Sponsored by
Erasmus Medical Center
About
Eligibility
Locations
Arms
Outcomes
Full info

About this trial

This is an interventional treatment trial for Ventricular Tachycardia focused on measuring epicardial catheter ablation

Eligibility Criteria

18 Years - undefined (Adult, Older Adult)All SexesDoes not accept healthy volunteers

Inclusion Criteria:

  1. clinical indication for ablation of a monomorphic ventricular tachycardia referred to one of the participating ablation centers
  2. history of ischemic heart disease
  3. ICD carrier or ICD implantation planned after the ablation
  4. informed written consent

Exclusion Criteria:

  1. current unstable angina as defined by current european guidelines
  2. AMI < 30 days or in case of incessant VT < 14 days
  3. absence of visualisation of the coronary anatomy (coronary angiogram /CT-angiogram)
  4. significant coronary stenosis approachable and clinically relevant for intervention
  5. presence of a mobile left ventricle thrombus seen on (contrast) echocardiography or MRI
  6. previous pericarditis
  7. presence of mitral/aortic mechanical valves prosthesis; previous coronary artery bypass graft; any other thoracic surgery that could cause pericardial adhesions
  8. previous thoracic radiation therapy
  9. contra-indication for general anaesthesia
  10. age below 18 years

Sites / Locations

    Arms of the Study

    Arm 1

    Arm 2

    Arm Type

    Experimental

    Active Comparator

    Arm Label

    combined endo/epicardial approach

    stepwise approach

    Arm Description

    combining endocardial scar homogenization with epicardial scar homogenization in the first VT ablation approach

    endocardial scar homogenization only at the first VT ablation procedure

    Outcomes

    Primary Outcome Measures

    Recurrence (Recurrence of any ventricular tachycardia)
    Recurrence of any ventricular tachycardia: any appropriate ICD therapy or VT > 30 seconds of duration recorded by ICD interrogations or on clinical event recorded by electrocardiogram with an initial blanking period of 1 week after the ablation procedure

    Secondary Outcome Measures

    procedure success
    success: non-inducibility of any sustained monomorphic VT partial success: non-inducibility of clinical VT (inducibility of non-clinical VT excluding polymorphic VT, VT with cycle length < 200ms)
    procedure related (serious) adverse events
    major: death, acute myocardial infarction (AMI) / coronary artery damage, major bleeding - type III and V, abdominal bleeding, tamponade > 80cm3, late tamponade, ischemic cerebral event minor: dry right ventricle puncture, drainable hemopericardium, postprocedural precordial pain, phrenic nerve injury, minor bleeding - type II
    procedure time, fluoroscopy and radiofrequency time
    time to recurrence to ventricular arrhythmia
    number of appropriate ICD therapy on follow-up
    number of ventricular arrhythmia related hospitalizations
    free of antiarrhythmic drugs on follow-up
    repeat procedure
    incessant VT or VT storm on follow-up
    mortality

    Full Information

    First Posted
    January 27, 2015
    Last Updated
    February 6, 2015
    Sponsor
    Erasmus Medical Center
    search

    1. Study Identification

    Unique Protocol Identification Number
    NCT02358746
    Brief Title
    Ventricular Tachycardia in Ischemic Cardiomyopathy; a Combined Endo-Epicardial Ablation Within the First Procedure Versus a Stepwise Approach
    Acronym
    EPILOGUE
    Official Title
    Ventricular Tachycardia in Ischemic Cardiomyopathy; a Combined Endo-Epicardial Ablation Within the First Procedure Versus a Stepwise Approach a Randomized Controlled Trial
    Study Type
    Interventional

    2. Study Status

    Record Verification Date
    February 2015
    Overall Recruitment Status
    Unknown status
    Study Start Date
    May 2015 (undefined)
    Primary Completion Date
    May 2019 (Anticipated)
    Study Completion Date
    December 2019 (Anticipated)

    3. Sponsor/Collaborators

    Responsible Party, by Official Title
    Principal Investigator
    Name of the Sponsor
    Erasmus Medical Center

    4. Oversight

    Data Monitoring Committee
    Yes

    5. Study Description

    Brief Summary
    Rationale: Nowadays ventricular tachycardia (VT) ablation in structural heart disease is performed primarily by early referral; while at the same time we still struggle with the limited longterm ablation success of endocardial VT ablation. An underestimated number of VTs from ischemic substrate have an epicardial exit. However, one cannot accurately predict who is in need of epicardial ablation. The investigators hypothesise endo/epicardial substrate homogenization in a first approach to be superior to endocardial substrate homogenization alone, in terms of recurrence on follow-up. Objective: To show superiority of a combined endo/epicardial approach compared to a stepwise approach in the ablation of ventricular tachycardia in a population with ischemic cardiomyopathy on VT recurrence. Study design: Multicenter prospective open randomized controlled trial. Study population: All patients above 18 years with an ischemic cardiomyopathy being referred for a ventricular tachycardia ablation. Intervention: One group undergoes endo/epicardial ablation and the other group has endocardial ablation only as a first approach. Main study parameters/endpoints: The main study endpoint is the difference in recurrences of ventricular tachycardia on follow-up - clinical or on implantable cardioverter defibrillator (ICD) interrogation - between the two ablation groups; secondary endpoints are procedure success and safety.

    6. Conditions and Keywords

    Primary Disease or Condition Being Studied in the Trial, or the Focus of the Study
    Ventricular Tachycardia, Ischemic Cardiomyopathy
    Keywords
    epicardial catheter ablation

    7. Study Design

    Primary Purpose
    Treatment
    Study Phase
    Not Applicable
    Interventional Study Model
    Parallel Assignment
    Masking
    None (Open Label)
    Allocation
    Randomized
    Enrollment
    125 (Anticipated)

    8. Arms, Groups, and Interventions

    Arm Title
    combined endo/epicardial approach
    Arm Type
    Experimental
    Arm Description
    combining endocardial scar homogenization with epicardial scar homogenization in the first VT ablation approach
    Arm Title
    stepwise approach
    Arm Type
    Active Comparator
    Arm Description
    endocardial scar homogenization only at the first VT ablation procedure
    Intervention Type
    Other
    Intervention Name(s)
    combined endo/epicardial approach
    Other Intervention Name(s)
    endo /epicardial catheter ablation
    Intervention Type
    Other
    Intervention Name(s)
    stepwise approach
    Intervention Description
    endocardial scar homogenization only at the first VT ablation procedure
    Primary Outcome Measure Information:
    Title
    Recurrence (Recurrence of any ventricular tachycardia)
    Description
    Recurrence of any ventricular tachycardia: any appropriate ICD therapy or VT > 30 seconds of duration recorded by ICD interrogations or on clinical event recorded by electrocardiogram with an initial blanking period of 1 week after the ablation procedure
    Time Frame
    2 years
    Secondary Outcome Measure Information:
    Title
    procedure success
    Description
    success: non-inducibility of any sustained monomorphic VT partial success: non-inducibility of clinical VT (inducibility of non-clinical VT excluding polymorphic VT, VT with cycle length < 200ms)
    Time Frame
    2 years
    Title
    procedure related (serious) adverse events
    Description
    major: death, acute myocardial infarction (AMI) / coronary artery damage, major bleeding - type III and V, abdominal bleeding, tamponade > 80cm3, late tamponade, ischemic cerebral event minor: dry right ventricle puncture, drainable hemopericardium, postprocedural precordial pain, phrenic nerve injury, minor bleeding - type II
    Time Frame
    30 days
    Title
    procedure time, fluoroscopy and radiofrequency time
    Time Frame
    one day
    Title
    time to recurrence to ventricular arrhythmia
    Time Frame
    2 years
    Title
    number of appropriate ICD therapy on follow-up
    Time Frame
    2 years
    Title
    number of ventricular arrhythmia related hospitalizations
    Time Frame
    2 years
    Title
    free of antiarrhythmic drugs on follow-up
    Time Frame
    2 years
    Title
    repeat procedure
    Time Frame
    2 years
    Title
    incessant VT or VT storm on follow-up
    Time Frame
    2 years
    Title
    mortality
    Time Frame
    2 years

    10. Eligibility

    Sex
    All
    Minimum Age & Unit of Time
    18 Years
    Accepts Healthy Volunteers
    No
    Eligibility Criteria
    Inclusion Criteria: clinical indication for ablation of a monomorphic ventricular tachycardia referred to one of the participating ablation centers history of ischemic heart disease ICD carrier or ICD implantation planned after the ablation informed written consent Exclusion Criteria: current unstable angina as defined by current european guidelines AMI < 30 days or in case of incessant VT < 14 days absence of visualisation of the coronary anatomy (coronary angiogram /CT-angiogram) significant coronary stenosis approachable and clinically relevant for intervention presence of a mobile left ventricle thrombus seen on (contrast) echocardiography or MRI previous pericarditis presence of mitral/aortic mechanical valves prosthesis; previous coronary artery bypass graft; any other thoracic surgery that could cause pericardial adhesions previous thoracic radiation therapy contra-indication for general anaesthesia age below 18 years
    Central Contact Person:
    First Name & Middle Initial & Last Name or Official Title & Degree
    Astrid Hendriks, MD
    Phone
    0031107032710
    Email
    a.a.hendriks@erasmusmc.nl
    First Name & Middle Initial & Last Name or Official Title & Degree
    Tamas Szilil-Torok, MD, PhD
    Phone
    031107035018
    Email
    t.szilitorok@erasmusmc.nl

    12. IPD Sharing Statement

    Learn more about this trial

    Ventricular Tachycardia in Ischemic Cardiomyopathy; a Combined Endo-Epicardial Ablation Within the First Procedure Versus a Stepwise Approach

    We'll reach out to this number within 24 hrs